Association between TyHGB and hyperuricemia and gout in patients with type-2 diabetes mellitus.
Triglyceride high-density cholesterol-glucose body index (TyHGB) has been identified as a reliable predictor for the risk of metabolic diseases. However, its significance concerning hyperuricemia and gout has not been investigated. Thus, this research aims to examine the link between TyHGB and the risk of hyperuricemia and gout in individuals with T2DM.
In this cross-sectional study, 2527 patients with T2DM admitted to the hospital between 2018 and 2023 were evaluated. Restricted cubic spline (RCS) and logistic regression techniques were utilized, along with further stratified and interaction analyses.
A positive linear association was identified between TyHGB and the prevalence of both hyperuricemia and gout. As TyHGB levels increased, there was a significant rise in the proportion of patients diagnosed with hyperuricemia or gout. Specifically, the prevalence of gout was 2.8%, 3.2%, 4.1%, and 10.4%, while the prevalence of hyperuricemia was 17.4%, 20.8%, 26.4%, and 42.7%, respectively. Multivariable logistic regression analysis revealed that each 1-unit increase in TyHGB was associated with a 15% increasing risk of hyperuricemia (OR = 1.15, 95% CI = 1.10, 1.19) and a 10% increasing risk of gout (OR = 1.10, 95% CI = 1.05, 1.15). Subgroup analyses indicated that this association was more pronounced in females. Furthermore, ROC analysis demonstrated that TyHGB exhibited a superior discriminatory performance compared to either TyG, TG/HDL, BMI, and FPG alone in predicting hyperuricemia (AUC = 0.666) and gout (AUC = 0.693).
TyHGB demonstrates a positive association with the risk of hyperuricemia and gout, highlighting its potential utility as a cost-effective biomarker for stratifying individuals at risk for these conditions.
Not applicable.
In this cross-sectional study, 2527 patients with T2DM admitted to the hospital between 2018 and 2023 were evaluated. Restricted cubic spline (RCS) and logistic regression techniques were utilized, along with further stratified and interaction analyses.
A positive linear association was identified between TyHGB and the prevalence of both hyperuricemia and gout. As TyHGB levels increased, there was a significant rise in the proportion of patients diagnosed with hyperuricemia or gout. Specifically, the prevalence of gout was 2.8%, 3.2%, 4.1%, and 10.4%, while the prevalence of hyperuricemia was 17.4%, 20.8%, 26.4%, and 42.7%, respectively. Multivariable logistic regression analysis revealed that each 1-unit increase in TyHGB was associated with a 15% increasing risk of hyperuricemia (OR = 1.15, 95% CI = 1.10, 1.19) and a 10% increasing risk of gout (OR = 1.10, 95% CI = 1.05, 1.15). Subgroup analyses indicated that this association was more pronounced in females. Furthermore, ROC analysis demonstrated that TyHGB exhibited a superior discriminatory performance compared to either TyG, TG/HDL, BMI, and FPG alone in predicting hyperuricemia (AUC = 0.666) and gout (AUC = 0.693).
TyHGB demonstrates a positive association with the risk of hyperuricemia and gout, highlighting its potential utility as a cost-effective biomarker for stratifying individuals at risk for these conditions.
Not applicable.